Dexcom
Coverage of Dexcom in the Nexus archive.
- Dexcom RCT suggests CGM benefits for broad diabetes population
A Dexcom randomized controlled trial (RCT) indicates that continuous glucose monitoring (CGM) offers benefits for a broad population of diabetes patients. The study's findings suggest CGM could be advantageous beyond specific subgroups.
- Stolen devices that failed quality control were sold to the public: FDA
The FDA reports that a medical company, Dexcom, discovered two lots of its Dexcom G7 continuous glucose monitoring devices were stolen by a third party and sold to the public after being intended for scrapping due to failed quality control.
- STAT+: Dexcom CEO hints at future uses for CGM
Dexcom CEO hints at future uses for CGM, and the author is attending the STAT Breakthrough Summit West in San Francisco. The summit features interviews with key figures like OpenEvidence CTO Zachary Ziegler. Readers can follow coverage on Statnews.com and social channels.
- Dexcom’s Bet Beyond Diabetes
Dexcom is exploring opportunities beyond diabetes, Dexcom is a company that specializes in glucose monitoring systems. The company is looking to expand its product offerings
- Show HN: GlycemicGPT – Open-source AI-powered diabetes management
GlycemicGPT is an open-source AI-powered diabetes management platform that connects continuous glucose monitors and insulin pumps to an AI analysis layer. It provides daily briefs, meal response analysis, and predictive alerting. The platform is self-hosted and does not deliver insulin or control pumps.
- STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and more
The article discusses OpenAI's health policy wishlist and other news from the health tech industry, including updates from Dexcom. The full story is available on STAT+. The newsletter covers how technology is transforming the life sciences.